Ken Griffin Caribou Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 6,800 shares of CRBU stock, worth $7,955. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,800
Previous 42,800
84.11%
Holding current value
$7,955
Previous $83,000
87.95%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CRBU
# of Institutions
138Shares Held
54.4MCall Options Held
21.2KPut Options Held
96.4K-
Black Rock Inc. New York, NY6.95MShares$8.13 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.57MShares$5.34 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.88MShares$4.54 Million0.4% of portfolio
-
Morgan Stanley New York, NY2.75MShares$3.22 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.5MShares$2.92 Million0.0% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $71.2M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...